AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19307014
Drug: Weekly topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly topotecan 3.5 mg/m(2) and docetaxel 30 mg/m(2) for 3 consecutive weeks, repeated every 4 weeks for 6 cycles or until disease progression, unacceptable toxicity, or death.
Trial: 19317960
Drug: fMRI-guided rTMS
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fMRI-guided rTMS treatment, details on dosage and duration not available
Trial: 19323966
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg daily titrated to 1 mg twice daily)
Trial: 19336742
Drug: Bortezomib (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.5 mg/m² on days 1, 4, 8, and 11, every 21 days)
Trial: 19339913
Drug: MTRR 66A>G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTRR 66A>G genotype (MTRR 66AA, AG, GG)
Trial: 19341509
Drug: Citalopram up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram up to 60 mg/d for up to 14 weeks
Trial: 19348029
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg once daily for 4 weeks, with possible escalation to 8 mg based on efficacy and tolerability assessment.
Trial: 19348029
Drug: Fesoterodine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine treatment satisfaction at week 12.
Trial: 19350213
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous glucose monitoring (CGMS) with norepinephrine therapy
Trial: 19350213
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous glucose monitoring (CGMS) without norepinephrine therapy
Trial: 19350213
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous glucose monitoring (CGMS)
Trial: 19358725
Drug: abacavir sulfate/lamivudine/zidovudine
RxNorm normalized name: Abacavir Sulfate/Lamivudine/Zidovudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily
Trial: 19358725
Drug: atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily
Trial: 19364933
Drug: Interferon beta-daclizumab
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta-daclizumab combination therapy (months 0-5.5)
Trial: 19364933
Drug: Daclizumab monotherapy
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daclizumab monotherapy (months 6.5-15.5)
Trial: 19364933
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta monotherapy
Trial: 19364933
Drug: Daclizumab (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1 mg/kg) as an intravenous infusion every 4 weeks
Trial: 19365012
Drug: Topical bevacizumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bevacizumab, 1.0% for 3 weeks
Trial: 19366446
Drug: Compassionate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassionate treatment with tumor-specific frequencies
Trial: 19369238
Drug: Sublingual application
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual application of 0.8 mg GTN
Trial: 19369372
Drug: Golden Rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golden Rice (65-98 g servings containing 0.99-1.53 mg beta-carotene) with 10 g butter
Trial: 19369372
Drug: [13C10]retinyl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [13C10]retinyl acetate reference dose (0.4-1.0 mg) in oil
Trial: 19371392
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m² (i.v. bolus days 1, 4, 8, 11) for up to eight 21-day cycles (C)
Trial: 19375217
Drug: High-dose exogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally for 1 week, 1 month, or until disease progression.
Trial: 19375217
Drug: High-dose exogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally.
Trial: 19376495
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (0.5 mg) administered as 3 consecutive monthly injections, followed by a variable-dosing regimen based on OCT criteria.
Trial: 19377385
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of OAC, aspirin and clopidogrel
Trial: 19380866
Drug: Bortezomib plus
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib plus chemotherapy
Trial: 19383032
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg q.d.)
Trial: 19386738
Drug: Iron excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron excretion in men
Trial: 19386738
Drug: Iron excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron excretion in menstruating women
Trial: 19386738
Drug: Iron excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron excretion in postmenopausal women
Trial: 19386738
Drug: Iron excretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron excretion in menstruating women (excluding hormonal contraceptive users)
Trial: 19389332
Drug: Lithium administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium administration for 4 weeks
Trial: 19394037
Drug: High-dose extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extended-release methylphenidate (OROS MPH) up to 1.5 mg/kg/d
Trial: 19394037
Drug: High-dose extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extended-release methylphenidate (OROS MPH)
Trial: 19398716
Drug: Ezatiostat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat hydrochloride (TLK199 tablets) at dose levels of 200 to 6000 mg/day
Trial: 19398716
Drug: Ezatiostat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat hydrochloride (TLK199 tablets)
Trial: 19399550
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative oral feeding (liquid diet on POD 2, soft diet on POD 3)
Trial: 19399946
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NT-proBNP, PetCO2, and clinical assessment
Trial: 19399946
Drug: NT-proBNP in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP in combination with clinical assessment
Trial: 19399946
Drug: NT-proBNP >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP > or = 2000 pg/mL and PetCO2 < or = 4 kPa
Trial: 19400961
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) offered in addition to telephone counselling
Trial: 19400961
Drug: No offer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No offer of Nicotine Replacement Therapy (NRT)
Trial: 19402886
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) at a dosage of 0.625 mg/d for 1 year
Trial: 19403641
Drug: High-fructose diet
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose diet (3.5 g x kg FFM(-1) x d(-1), +35% energy intake)
Trial: 19404953
Drug: Moderate dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dosage of prednisone (0.15-0.4 mg/kg/day)
Trial: 19415121
Drug: Customized therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized therapy based on BRCA1 mRNA levels
Trial: 19415121
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with low BRCA1
Trial: 19415121
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with intermediate BRCA1
Trial: 19415121
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with high BRCA1
Trial: 19419474
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod applied three to seven times per week for 16 weeks
Trial: 19421322
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 13 weeks
Trial: 19439093
Drug: Ezatiostat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat hydrochloride liposomes for injection (IV) at 5 dose levels (50, 100, 200, 400, and 600 mg/m2) on days 1 to 5 of a 14-day cycle
Trial: 19439093
Drug: Ezatiostat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat hydrochloride liposomes for injection (IV) at 600 mg/m2 on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle
Trial: 19439093
Drug: Ezatiostat hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezatiostat hydrochloride liposomes for injection
Trial: 19440083
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/d (smokers)
Trial: 19440083
Drug: Olanzapine 20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 20 mg/d (smokers)
Trial: 19440083
Drug: Olanzapine 40
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 40 mg/d (smokers)
Trial: 19440083
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg/d (nonsmokers)
Trial: 19440083
Drug: Olanzapine 20
RxNorm normalized name: olanzapine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 20 mg/d (nonsmokers)
Trial: 19440083
Drug: Olanzapine 40
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 40 mg/d (nonsmokers)
Trial: 19440083
Drug: Olanzapine 40
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 40 mg/d (African Americans)
Trial: 19440083
Drug: Olanzapine 40
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 40 mg/d (Whites)
Trial: 19443656
Drug: Adoptive immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T lymphocytes (CTLs) expanded from CB T cells.
Trial: 19454532
Drug: Alemtuzumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab (0.3 mg/kg/day for 4 days)
Trial: 19457240
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) (DrotAA) administered within 24 hours of first sepsis-induced organ dysfunction
Trial: 19457240
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) (DrotAA) administered after 24 hours of first sepsis-induced organ dysfunction
Trial: 19457245
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with CPT-11, 5-FU, and LV for 12 weeks (preoperative phase)
Trial: 19457245
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with the same regimen (CPT-11, 5-FU, and LV) for 12 weeks
Trial: 19457253
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before administration of tremelimumab)
Trial: 19459850
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with three peptides (TTK, LY6K, IMP-3) at 1 mg each, administered intradermally with 1 mL of incomplete Freund's adjuvant weekly for 5 weeks
Trial: 19463441
Drug: Biodegradable polymer-coated
RxNorm normalized name: dicresulene polymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodegradable polymer-coated sirolimus-eluting stent (Excel) with 6-month dual antiplatelet therapy
Trial: 19466962
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied three times weekly for up to 16 weeks
Trial: 19467341
Drug: F/S bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/S bid plus Zileuton 600 mg qid
Trial: 19470620
Drug: Cinacalcet (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (titrated from 30 mg twice daily to 90 mg four times daily during a titration phase of 2-16 weeks)
Trial: 19470631
Drug: Anastrozole, 1
RxNorm normalized name: Anastrozole, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole, 1 mg, daily for 6 months
Trial: 19471019
Drug: Lenalidomide 30
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide 30 mg/day once daily (days 1-21 every 28 days)
Trial: 19479077
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment at maintenance dose
Trial: 19479315
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine (LDD) Tc-99m-mibi gated-SPECT
Trial: 19483644
Drug: PSA: 154-163
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA: 154-163 (155L) vaccination with Montanide ISA-51, 1 mg, given subcutaneously 7 times on weeks 0, 2, 4, 6, 10, 14, and 18.
Trial: 19485285
Drug: Alpha-1 adrenergic
RxNorm normalized name: Alpha-1 adrenergic receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-1 adrenergic blocker (A1AB) use
Trial: 19488737
Drug: Hyperglycaemia clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia clamp study (glucose at 11 mmol/l)
Trial: 19492661
Drug: Intradermal skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal skin testing (ST)
Trial: 19492661
Drug: Epinephrine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.2 mL of a 1:1,000 dilution) intramuscularly
Trial: 19493369
Drug: Citalopram up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram up to 60 mg/day for up to 14 weeks
Trial: 19494218
Drug: Anakinra (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (recombinant interleukin-1-receptor antagonist)
Trial: 19496252
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium
Trial: 19497063
Drug: Treatment options
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment options reviewed
Trial: 19498019
Drug: Bortezomib once
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib once weekly (0.7-1.6 mg/m²; days 1, 8, 15, and 22; 35-day cycles)
Trial: 19498019
Drug: Bortezomib twice
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib twice weekly (0.7-1.3 mg/m²; days 1, 4, 8, and 11; 21-day cycles)
Trial: 19498019
Drug: Both once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both once-weekly and twice-weekly bortezomib
Trial: 19502645
Drug: Prompt revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt revascularization with intensive medical therapy
Trial: 19502645
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy in CABG stratum
Trial: 19502645
Drug: Insulin-provision group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-provision group
Trial: 19502645
Drug: Insulin-sensitization group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-sensitization group
Trial: 19505676
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (contralateral glaucomatous eyes receiving antiglaucoma medications)
Trial: 19506189
Drug: 15-mL bottle
RxNorm normalized name: bottlebrush pollen extract 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-mL bottle
Trial: 19506189
Drug: 2.5-mL bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-mL bottle
Trial: 19507806
Drug: OROS hydromorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS hydromorphone (individualized doses), administered once daily.
Trial: 19508731
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d
Trial: 19508997
Drug: Higher intake
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher intake of DHA (>=64.0 mg/day)
Trial: 19508997
Drug: Higher intake
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher intake of EPA (>=42.3 mg/day)
Trial: 19509175
Drug: Pazopanib 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 300 mg twice daily
Trial: 19509175
Drug: Pazopanib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (various doses)
Trial: 19515473
Drug: Home BP
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home BP measured 3 times daily for 1 week using a validated oscillometric monitor.
Trial: 19520420
Drug: PLD 30
RxNorm normalized name: pLDLR-Neo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m² followed by carboplatin AUC 5 mg/mL/minute every 4 weeks
Trial: 19524963
Drug: Denosumab (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (180 mg subcutaneous every 4 weeks or every 12 weeks)
Trial: 19524963
Drug: Intravenous bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bisphosphonates (every 4 weeks)
Trial: 19542735
Drug: Lanreotide Autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel (ATG) 120 mg injections every 4-8 weeks
Trial: 19546056
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous pramlintide infusion (CSPI) at 9 microg/h with premeal bolus doses starting at 15 microg and titrated to 60 microg
Trial: 19549740
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (NAL-GLU, 150 microg/kg sc) followed by GnRH doses of 25, 75, 250, or 750 ng/kg iv every 4 h
Trial: 19549995
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing (53% overall)
Trial: 19549995
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics prescribed (control group)
Trial: 19553641
Drug: Olaparib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (600 mg twice daily)
Trial: 19553641
Drug: Olaparib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (10 mg daily for 2 of every 3 weeks)
Trial: 19555842
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of troponin T and copeptin
Trial: 19555842
Drug: Copeptin <14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin <14 pmol/l and troponin T < or =0.01 microg/l
Trial: 19556425
Drug: Immunotherapy (autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (autologous leukemia cells with GM-CSF-secreting K562 cells)